Top Industry News

In one of the largest deals thus far in 2026, Sun Pharmaceutical Industries, a Mumbai, India-based bio/pharmaceutical company, has agreed to acquire Organon & Co., the former women’s health, biosimilars, and established brand business of…

Gilead Sciences has completed its $7.8-billion acquisition of Arcellx, a bio/pharmaceutical company focused on oncology. The deal was announced in February (February 2026).  Kite, a subsidiary of Gilead Sciences, and Arcellx had an existing collaboration to co-develop and co-commercialize Arcellx’s lead…

Eli Lilly and Company has agreed to acquire Ajax Therapeutics, a bio/pharmaceutical company developing JAK inhibitors for treating myeloproliferative neoplasms, a group of rare, chronic blood cancers, for $2.3 billion.  JAK inhibitors are a class of targeted…

The latest from CDMOs, CMOs, and suppliers featuring WuXi Biologics, Thermo Fisher Scientific, and PCI Pharma Services, Mikart and Benuvia. Biologics Manufacturing * WuXi Biologics Announces Structural Completion of Microbial Mfg Facility  * Thermo Fisher…

A roundup of news from the large and mid-sized bio/pharmaceutical companies featuring Chiesi Group, Eli Lilly and Company, AbbVie and Teva. Highlights below.   For the latest news roundup on small and Emerging Pharma companies,…

The latest from small and Emerging Pharma companies featuring Seaport Therapeutics, Avalyn Pharma & Hemab Therapeutics.  For news on the large and mid-sized bio/pharmaceutical companies, see Global Briefs.  * Seaport Announces $212-M IPO To Support…

AbbVie has announced a $1.4-billion investment to build a new 185-acre pharmaceutical manufacturing campus in Durham, North Carolina. The investment is part of the company’s $100-billion, 10-year capital investment plan in the US, which includes R&D and manufacturing,…

Merck & Co. and Google Cloud have announced a multi-year partnership, worth up to $1 billion, to enhance Merck’s digital backbone in artificial intelligence (AI) by deploying an agentic AI platform across Merck’s research & development (R&D), manufacturing, commercial, and corporate functions.  The partnership includes…

Eli Lilly and Company has agreed to acquire Kelonia Therapeutics, a Boston-based clinical-stage bio/pharmaceutical company specializing in in vivo gene delivery, in a $7-billion deal ($3.25 billion upfront and $3.75 billion in milestone payments).  Kelonia has developed a proprietary in vivo gene-placement system, iGPS, which uses specially engineered…

Servier, a French bio/pharmaceutical company, has completed its $2.5-billion acquisition of Day One Biopharmaceuticals, a Brisbane, California-based bio/pharmaceutical developing oncology drugs. The companies had announced the acquisition last month (March 2026).   Day One’s portfolio…